Fu J - Search Results

1

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Yan YD, Cui JJ, Fu J, Su YJ, Chen XY, Gu ZC, Lin HW. Yan YD, et al. Among authors: fu j. Front Immunol. 2021 Dec 3;12:760737. doi: 10.3389/fimmu.2021.760737. eCollection 2021. Front Immunol. 2021. PMID: 34925331 Free PMC article.

2

Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review.

Fu J, Liu Y, Lin H, Wu B. Fu J, et al. Clin Drug Investig. 2018 Dec;38(12):1167-1178. doi: 10.1007/s40261-018-0706-5. Clin Drug Investig. 2018. PMID: 30232698

3

First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis.

Su Y, Fu J, Du J, Wu B. Su Y, et al. Among authors: fu j. Ther Adv Med Oncol. 2020 Aug 17;12:1758835920950199. doi: 10.1177/1758835920950199. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32874210 Free PMC article.

4

Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.

Yan YD, Zhao Y, Zhang C, Fu J, Su YJ, Cui XL, Ma EL, Liu BL, Gu ZC, Lin HW. Yan YD, et al. Among authors: fu j. EClinicalMedicine. 2022 Jul 1;50:101535. doi: 10.1016/j.eclinm.2022.101535. eCollection 2022 Aug. EClinicalMedicine. 2022. PMID: 35812997 Free PMC article.

5

Applications of machine learning in tumor-associated macrophages.

Li Z, Yu Q, Zhu Q, Yang X, Li Z, Fu J. Li Z, et al. Among authors: fu j. Front Immunol. 2022 Sep 23;13:985863. doi: 10.3389/fimmu.2022.985863. eCollection 2022. Front Immunol. 2022. PMID: 36211379 Free PMC article. Review.

6

Adherence to endocrine therapy in patients with hormone receptor-positive early-stage breast cancer: a retrospective study.

Yan YD, Fu J, Gu ZC, Lu JS, Su YJ, Lin HW. Yan YD, et al. Among authors: fu j. Int J Clin Pharm. 2023 Feb;45(1):184-190. doi: 10.1007/s11096-022-01450-3. Epub 2022 Nov 16. Int J Clin Pharm. 2023. PMID: 36383338

7

Brachytherapy for cervical cancer: from intracavitary to interstitial technique.

Yang X, Ren H, Li Z, Fu J. Yang X, et al. Among authors: fu j. Front Oncol. 2024 Nov 6;14:1442712. doi: 10.3389/fonc.2024.1442712. eCollection 2024. Front Oncol. 2024. PMID: 39568565 Free PMC article. Review.

8

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.

Lu S, Ye M, Ding L, Tan F, Fu J, Wu B. Lu S, et al. Among authors: fu j. Oncotarget. 2017 Feb 7;8(6):9996-10006. doi: 10.18632/oncotarget.14310. Oncotarget. 2017. PMID: 28036283 Free PMC article.

9

Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung.

Zhu J, He W, Ye M, Fu J, Chu YB, Zhao YY, Zhang YJ, Kuo D, Wu B. Zhu J, et al. Among authors: fu j. Future Oncol. 2018 Nov;14(27):2833-2840. doi: 10.2217/fon-2018-0321. Epub 2018 Jun 7. Future Oncol. 2018. PMID: 29878848

10

Oncologic outcomes of pre- versus post-operative radiation in Resectable soft tissue sarcoma: a systematic review and meta-analysis.

Yang X, Zhang L, Yang X, Yu W, Fu J. Yang X, et al. Among authors: fu j. Radiat Oncol. 2020 Jun 23;15(1):158. doi: 10.1186/s13014-020-01600-9. Radiat Oncol. 2020. PMID: 32576267 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13,064 results

Search Page

Filters